Clinitech Laboratory IPO Review

Clinitech Laboratory Limited is one of the most respected diagnostic centres and pathology labs. As they complete more than 30 years in this industry, they are committed to sticking to the highest standards of service by embracing new technologies and delivering it with excellent efficiency.

The Company is led by highly professional Promoters, JAGDISH UMAKANT NAYAK , JYOTI JAGDISH NAYAK AND ASHUTOSH JAGDISH NAYAK, who have 30+ years of experience in diagnostic business.

 Financially, Clinitech Laboratory revenue is stable from ₹645.70 Lakhs in FY22 to ₹636.34 Lakhs in FY23 and currently at ₹643.92 Lakhs in FY24. Similarly, EBITDA is also stable from ₹113.92 Lakhs in FY22 to ₹136.69 Lakhs in FY23 and currently at ₹101.66 Lakhs in FY24. The PAT is also stable from ₹51.26 Lakhs in FY22 to ₹61.31 Lakhs in FY23 and currently at ₹37.12 Lakhs in FY24. This indicates a steady financial performance.

For the Clinitech Laboratory IPO, the company is issuing shares at a pre-issue EPS of ₹2.20 and a post-issue EPS of ₹1.62. The pre-issue P/E ratio is 43.63x, while the post-issue P/E ratio is 59.25x against the industry P/E ratio of 57.74x. The company's ROCE for FY24 is 12.00% and ROE for FY24 is 0.10%. These metrics suggest that the IPO is fully priced.

The Grey Market Premium (GMP) of Clinitech Laboratory indicates potential listing gains of 0%. Given the company's financial performance and the valuation of the IPO, we recommend Investors to avoid the Clinitech Laboratory IPO for listing gain or Long term investment purposes.